US4547368A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hepatitis B core antigen vaccine made by recombinant DNA
Assignee: United States Department of Health and Human Services
•
Filing: 1984-08-06
•
Granted: 1985-10-15
•
Expires: 2004-08-06
Abstract
Abstract Disclosed is a a vaccine effective for primates, such as chimpanzees, and against hepatitis B virus (HBV) using hepatitis B core antigen (HBcAg) made by recombinant DNA. Chimpanzees immunized with the vaccine were protected against hepatitis B.
Inventors
- 👤 Edward Tabor
- 👤 Robert J. Gerety
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 16:44
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; C12; C12N; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
50 words
A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the supernatant fluid of cloned cells containing recombinant hepatitis B virus DNA, mixing said HBcAg with a suitable adjuvant to form a vaccine, and injecting said vaccine into a chimpanzee.
Claim 2
Independent Claim
50 words
A method of protecting chimpanzees by administering a vaccine prepared by a process which comprises centrifuging and isolating HBcAg from the supernatant fluid of cloned cells containing recombinant hepatitis B virus DNA, mixing said HBcAg with a suitable adjuvant to form a vaccine, and injecting said vaccine into a chimpanzee.
Claim 3
Independent Claim
38 words
A method of protecting chimpanzees from hepatitis B virus which comprises subcutaneously injecting said chimpanzees with a vaccine which is a mixture of (a) HBcAg prepared from cloned cells containing recombinant hepatitis B virus DNA and (b) HBsAg.
Claim 4
Independent Claim
38 words
A method of protecting chimpanzees from hepatitis B virus which comprises subcutaneously injecting said chimpanzees with a vaccine which is a mixture of (a) HBcAg prepared from cloned cells containing recombinant hepatitis B virus DNA and (b) HBsAg.
Claim 5
Dependent Claim
29 words
The method of claim 2 in which HBcAg is present in the amount of approximately 50 μg and the HBsAg is present in the amount of approximately 20 μg.
References Cited (Backward Citations)
US4100267A
Cited
US4102996A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-10-14 | 1989-04-15 | 1989-10-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-10-14 | 1993-04-15 | 1993-10-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-10-14 | 1997-04-15 | 1997-10-15 | $7700.00 | Window Closed / Lapsed |